1. Home
  2. ADMA vs HAE Comparison

ADMA vs HAE Comparison

Compare ADMA & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADMA
  • HAE
  • Stock Information
  • Founded
  • ADMA 2004
  • HAE 1971
  • Country
  • ADMA United States
  • HAE United States
  • Employees
  • ADMA N/A
  • HAE N/A
  • Industry
  • ADMA Biotechnology: Biological Products (No Diagnostic Substances)
  • HAE Medical/Dental Instruments
  • Sector
  • ADMA Health Care
  • HAE Health Care
  • Exchange
  • ADMA Nasdaq
  • HAE Nasdaq
  • Market Cap
  • ADMA 4.1B
  • HAE 3.9B
  • IPO Year
  • ADMA N/A
  • HAE 1991
  • Fundamental
  • Price
  • ADMA $16.32
  • HAE $79.94
  • Analyst Decision
  • ADMA Strong Buy
  • HAE Strong Buy
  • Analyst Count
  • ADMA 4
  • HAE 9
  • Target Price
  • ADMA $21.25
  • HAE $108.78
  • AVG Volume (30 Days)
  • ADMA 2.3M
  • HAE 447.0K
  • Earning Date
  • ADMA 02-26-2025
  • HAE 02-06-2025
  • Dividend Yield
  • ADMA N/A
  • HAE N/A
  • EPS Growth
  • ADMA N/A
  • HAE N/A
  • EPS
  • ADMA 0.28
  • HAE 2.41
  • Revenue
  • ADMA $382,809,000.00
  • HAE $1,361,223,000.00
  • Revenue This Year
  • ADMA $67.03
  • HAE $7.56
  • Revenue Next Year
  • ADMA $14.58
  • HAE $3.13
  • P/E Ratio
  • ADMA $58.22
  • HAE $32.95
  • Revenue Growth
  • ADMA 63.39
  • HAE 9.84
  • 52 Week Low
  • ADMA $4.82
  • HAE $70.25
  • 52 Week High
  • ADMA $23.64
  • HAE $97.97
  • Technical
  • Relative Strength Index (RSI)
  • ADMA 36.43
  • HAE 50.92
  • Support Level
  • ADMA $17.82
  • HAE $75.63
  • Resistance Level
  • ADMA $18.88
  • HAE $81.50
  • Average True Range (ATR)
  • ADMA 0.84
  • HAE 2.28
  • MACD
  • ADMA -0.08
  • HAE 0.28
  • Stochastic Oscillator
  • ADMA 12.01
  • HAE 77.75

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: